

# Deimmunization, Class II Immunogenicity (CD4EpiScore), Naturally Processed (MHCII-NP) peptide predictions

Sandeep Kumar Dhanda

[sdhanda@lji.org](mailto:sdhanda@lji.org)

IEDB user workshop 2018

Oct 22-23, 2018

# Deimmunization tool

# Deimmunization tool: Background

- Native and engineered proteins are widely used to treat a variety of ailments.
- Non-self nature of engineered proteins may cause immunogenicity
- Self protein (e.g. EPO) can also be immunogenic, when administered in high dose
- Immunogenicity of therapeutic proteins may be associated with safety issues.
- These therapeutic proteins can be de-immunized by removal of T cell epitopes (King et al. 2014)

# Deimmunization tool

- To remove the epitope based on binding affinities to a set of reference MHC II alleles.
- The tool is optimized on EPO data (Tangri et. al. 2005).
- The concept of deimmunization was experimentally tested on '**Vatreptacog alpha**': a drug discontinued in clinical trial phase III due to immunogenicity issues.
- Steps
  - Predict the immunogenic regions in given sequence
  - Suggest amino acid substitution.
- Published in Immunology (Dhandra et al. 2018)

# Predicting immunogenic regions

<http://tools.iedb.org/deimmunization/>

Home

Help

Example

Reference

Contact

## Deimmunization tool

Step 1/2 (Predicting Immunogenic regions in the given protein sequence/s)

### Specify Sequence(s)

Enter epitope sequence(s) in FASTA format

```
>sp|P01588|EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1
APPRLICDSRVLERYLLEAKEAENITTGCAEHC
SLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQ
L
HVDKAVSGLRSLTLLLRALGAQKEAISPPDAASAAPLRITITADTFRKLFVYSNFLRGKL
KLYTGEACRTGDR
```

Or upload epitope sequence(s) from a file

Choose File No file chosen

### Select Median Percentile Rank Threshold

Select maximum median percentile rank threshold: ?

20

Go to Next step

Reset

# Predicting immunogenic regions

APPRLICDSRVLERYLLEAKEAEENITTTGCAEHCSLNENITVPDTKVNIFYAWKRMEVGGQQAVEVWQG  
 LALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLRLALGAQKEAISPDAASAAPLRT  
 ITADTFRKLFVYSNFLRGKLLKLYTGEACRTGDR

Generating overlapping peptides from given protein sequence.

All 15mer, overlapping 10 amino acids.

APPRLICDSRVLERY	1-15	38.89	Non-immunogenic
ICDSRVLERYLLEAK	6-20	60.39	Non-Immunogenic
VLERYLLEAKEAEENI	11-25	23.46	Non-immunogenic
LLEAKEAEENITTTGCA	16-30	21.76	Non-immunogenic
-----			
DTFRKLFRVYSNFLR	136-150	6.08	Immunogenic

Allele : A set of 26 reference MHC class II alleles (Greenbaum et al. 2011) covering 95% of populations.

Method : IEDB Recommended, which is a consensus of three methods for predicting MHC class II binding.

Median Percentile Rank: Take the median value of consensus percentile rank from 26 alleles.

Lower Rank corresponds to MHC binding.

Default threshold of median percentile rank is  $\leq 20$

User can change the threshold

# Deimmunization tool – Intermediate page

## IEDB Analysis Resource

[Home](#) [Help](#) [Example](#) [Reference](#) [Contact](#)

### Deimmunization tool (Peptide mutant prediction)

The prediction may take about more than 10 minutes. We recommend you to leave your email address to ensure you receive the result.

Step 2/2 (Predicting non-immunogenic variants of selected immunogenic peptides)

#### Choose Immunogenic peptides for deimmunization

Protein Number	Start Position	End Position	Median Percentile Rank	Peptide	Select Peptide/s
1	136	150	6.08	DTRKLFQVYSNFL	<input checked="" type="checkbox"/>
1	61	75	8.355	VEWQGLALLSEAV	<input type="checkbox"/>
1	101	115	9.92	GLRSLTLLRALGAC	<input type="checkbox"/>

#### Choose threshold for deimmunization

Select the cutoff value for the difference in median percentile Rank :

8.5

#### Enter Job Details

Enter the Job Name (Optional)

Job name (option)

Enter your Email Address (Recommended)

Your email address (o)


Submit

Reset

# Suggest amino acid substitutions

DTFRKLF~~R~~VYSNFLR 136-150 6.08 Immunogenic

Generate all possible possible analogs in the selected 15mer (19\*15) = 285  
 Predict immunogenicity with the same approach (as in step 1)

Protein Number	Peptide	Peptide ID	Start Position	End Position	Median Percentile Rank	Median Difference 
1	DTFRKLF <del>R</del> VYSNFLR	wild	136	150	6.08	0.0
1	DTFRKLD <del>R</del> VYSNFLR	F142D	136	150	18.88	12.8
1	DTFRKLG <del>R</del> VYSNFLR	F142G	136	150	17.84	11.76
1	DTFRKLE <del>R</del> VYSNFLR	F142E	136	150	17.25	11.17
1	DTFRKLF <del>R</del> VYSNF <del>D</del> R	L149D	136	150	17.225	11.145
1	DTFRKLP <del>R</del> VYSNFLR	F142P	136	150	17.11	11.03
1	DTFRKLP <del>R</del> VYSNFLR	L141P	136	150	16.89	10.81
1	DTFRKLF <del>R</del> VYSNF <del>G</del> R	L149G	136	150	16.265	10.185
1	DTFRKLF <del>R</del> CVYSNFLR	V144C	136	150	15.405	9.325
1	DTFRKLF <del>R</del> VYSNF <del>N</del> R	L149N	136	150	15.11	9.03
1	DTFRKLF <del>R</del> RVYSNFLR	F142H	136	150	14.9	8.82

These substitutions may have affected the neighboring peptides.

In a 15mer (overlapping 10mer), two neighbors can get affected.

RTITADTFRKLD~~R~~VY 131-145  
 DTFRKL~~D~~RVYSNFLR 136-150  
 L~~D~~RVYSNFLRGK~~L~~KL 141-155

Threshold is based on the difference of median percentile rank

Default is  $\geq 8.5$  (in this case  $6.08 + 8.5 = 14.51$ )

Any peptide analog with median percentile rank of  $\geq 14.51$  will be suggested

User can change the threshold



# Suggest amino acid substitutions

Protein Number	Peptide	Peptide ID	Start Position	End Position	Median Percentile Rank	Median Difference <sup>?</sup>	C terminal Neighbor 1 (Median)	C terminal Neighbor 2 (Median)	N terminal Neighbor 1 (Median)	N terminal Neighbor 2 (Median)	Deimmunization Score <sup>?</sup>
1	<b>D</b> TFRKLFRVYSN <b>F</b> L <b>R</b>	wild	136	150	6.08	0.0	10.35	24.645	28.525	26.645	NA
1	D <b>T</b> FRKL <b>D</b> RVYSN <b>F</b> L <b>R</b>	F142D	136	150	18.88	12.8	18.17	NA	35.715	NA	3.0
1	D <b>T</b> FRKL <b>G</b> RVYSN <b>F</b> L <b>R</b>	F142G	136	150	17.84	11.76	15.1	NA	30.99	NA	3.0
1	D <b>T</b> FRKL <b>E</b> RVYSN <b>F</b> L <b>R</b>	F142E	136	150	17.25	11.17	15.615	NA	33.405	NA	3.0
1	D <b>T</b> FRKLFRVYSN <b>F</b> <b>D</b> <b>R</b>	L149D	136	150	17.225	11.145	30.055	45.8	NA	NA	3.0
1	D <b>T</b> FRKL <b>P</b> RVYSN <b>F</b> L <b>R</b>	F142P	136	150	17.11	11.03	16.61	NA	31.26	NA	3.0
1	D <b>T</b> FRK <b>P</b> RVYSN <b>F</b> L <b>R</b>	L141P	136	150	16.89	10.81	14.09	NA	40.215	NA	3.0
1	D <b>T</b> FRKLFRVYSN <b>F</b> <b>G</b> <b>R</b>	L149G	136	150	16.265	10.185	24.185	43.53	NA	NA	3.0
1	D <b>T</b> FRKL <b>F</b> <b>R</b> CYSN <b>F</b> L <b>R</b>	V144C	136	150	15.405	9.325	16.455	NA	30.845	NA	3.0
1	D <b>T</b> FRKLFRVYSN <b>F</b> <b>N</b> <b>R</b>	L149N	136	150	15.11	9.03	15.69	40.485	NA	NA	3.0
1	D <b>T</b> FRKL <b>H</b> RVYSN <b>F</b> L <b>R</b>	F142H	136	150	14.9	8.82	10.545	NA	29.675	NA	3.0

## Possible scenarios

1. Neighboring peptides absent (for terminal residues or small peptides)
2. Immunogenicity is reduced for peptides
3. Immunogenicity remain the same (No effect)
4. Increased immunogenicity

# Deimmunization score

Immunogenicity for Neighboring peptide (1)	Immunogenicity for Neighboring peptide (2)	Score
Absent	Absent	1
Absent	Reduced	2
Reduced	Reduced	3
Absent	Neutral	4
Reduced	Neutral	5
Neutral	Neutral	6
Absent	Increased	7
Reduced	Increased	8
Neutral	Increased	9
Increased	Increased	10




# CD4EpiScore tool

Prediction of CD4 T cell epitope

# T cell epitopes: Current approaches

- MHC binding prediction
  - Need allele information
  - Several methods available at IEDB
  - Individual based approach
- Promiscuous binders
  - Binding to several alleles
  - 27 Reference alleles (Greenbaum et al. 2011)
  - Population based approach
- Immunodominant epitopes
  - Immunogenic in broader population
  - Based on 7-allele method (Paul et al. 2015)
  - Population based approach

# CD4 T cell epitopes



# MHC class II binding and immunogenicity

The Majority of Immunogenic Epitopes Generate CD4<sup>+</sup> T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues

Paula Y. Arnold, Nicole L. La Gruta, Tim Miller, Kate M. Vignali, P. Scott Adams, David L. Woodland and Dario A. A. Vignali

J Immunol July 15, 2002, 169 (2) 739-749; DOI: <https://doi.org/10.4049/jimmunol.169.2.739>


## A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition

Zarixia Zavala-Ruiz<sup>†</sup>, Iwona Strug<sup>‡</sup>, Bruce D. Walker<sup>§</sup>, Philip J. Norris<sup>¶||</sup>, and Lawrence J. Stern<sup>\*||</sup>

European Journal of  
**Immunology**

Article |  Free Access

## Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor

Derek B. Sant'Angelo , Eve Robinson, Charles A. Janeway, Jr., Lisa K. Denzin


First published: 22 August 2002

# CD4EpiScore

- To predict epitope score for CD4 T cells or class II immunogenicity.
- Based on Neural network model trained on
  - In house dataset for different antigens tested on different population cohorts
  - Tetramer dataset- derived from IEDB
- Validated on 57 independent studies from different groups across the world
- Implemented three approaches
  - 7-allele method (Paul et. al. 2015)
  - Immunogenicity predictions
  - Hybrid approach

# Immunogenicity predictions

$$\text{Combined score} = \alpha \times \text{Imm score} + (1 - \alpha) \times \text{HLA score.}$$



Immunogenicity Score: Derived from the neural network model trained on Immunogenicity data

HLA Score: Derived from HLA binding affinity using 7-allele method (Paul et. al. 2015).

Dhanda et. al. 2018, *Frontiers in Immunology*, 9, 1369



# CD4EpiScore: Input page

<http://tools.iedb.org/CD4EpiScore>

[Home](#) [Help](#) [Example](#) [Reference](#) [Contact](#)

## CD4 T cell immunogenicity prediction

Specify Sequence(s)	
Enter epitope sequence(s) in PLAIN or FASTA format	<pre>&gt;sp P01588 EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1 MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITGCAEHC SLNENITVPDTKVNFYAWKRMEVGGQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQL HVDKAVSGLRSLTTLRLALGAQKEAISPPDAASAAPLRTITADTFRKLFVYYSNFLRGKL KLYTGACRTGDR</pre>
Or upload epitope sequence(s) from a file	<input type="button" value="Choose File"/> No file chosen
Choose a prediction method	
Prediction method:	<input type="text" value="IEDB recommended (combined)"/>
<div><input checked="" type="checkbox"/> IEDB recommended (combined) 7-allele Immunogenicity</div>	
Specify Output	
Sort Peptides by:	<input type="text" value="Position in Protein"/>
Select maximum percentile rank threshold:	<input type="text" value="50"/>
Enter the Job Name (Optional)	<input type="text"/>
Email address (optional)	<input type="text"/>
<div><input checked="" type="checkbox"/> Score/Percentile Rank <input checked="" type="checkbox"/> Position in Protein</div>	
<input type="button" value="Submit"/> <input type="button" value="Reset"/>	

# CD4EpiScore: Results page

## CD4 Immunogenicity prediction results

Number of proteins: 1

Number of 15mer (overlapping 10mer): 37

Threshold : 50.0%

Method : combined

[Download result](#) 


[Citations](#)

Protein Number	Protein Description	Peptide	Start	End	Combine Score	Immunogenicity Score	Peptide core	Median Percentile Rank (7-allele)	HLA-DRB1:03:01	HLA-DRB1:07:01	HLA-DRB1:15:01	HLA-DRB3:01:01	HLA-DRB3:02:02	HLA-DRB4:01:01	HLA-DRB5:01:01
1	sp P01588 EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1	CPAWLWLLLSLLSLP	6	26	48.0978	99.7096	LWLLLSLLS	13.69	3.93	13.69	1.25	51.32	63.91	44.08	1.21
1	sp P01588 EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1	WLLLSLLSLPLGLPV	11	25	40.3825	95.0613	LLSLLSLPL	8.93	3.93	4.19	0.65	71.75	38.37	2.98	1.16
1	sp P01588 EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1	LGLPVLGAPPRLICD	21	35	48.0036	99.1292	LPVLGAPPR	13.92	10.76	13.92	15.07	22.97	9.63	49.41	1.87
1	sp P01588 EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1	RLICDSRVLERYLLE	31	45	49.6284	93.921	LICDSRVLE	20.1	0.17	41.0	20.1	33.39	16.1	23.4	19.74
1	sp P01588 EPO_HUMAN Erythropoietin OS=Homo sapiens GN=EPO PE=1 SV=1	ITVPDTKVNIFYAWKR	66	86	49.2266	88.9416	TKVNIFYAWK	22.75	22.75	35.9	13.47	22.15	60.35	61.81	9.97

# MHCII-NP

Prediction of class II naturally  
processed peptides

# CD4 T cell epitopes



# MHCII-NP


- Predicting the naturally processed peptides for MHC class II
- Based on
  - cleavage motif analysis at C and N terminal of peptides
  - Ligand elution data derived from IEDB
  - Ligand predictions is improved by combining the binding and cleavage motifs.
- T cell epitope prediction is not improved

# Ligand predictions

$$\text{Combined score} = \alpha \times \text{cleavage probability score} + (1 - \alpha) \times \text{binding score}$$

**Cleavage Score:** Derived from the cleavage motif analysis in ligand elution data

**Binding Score:** Derived from HLA binding affinity using 7-allele method (Paul et. al. 2015).



Paul et. al. 2018, *Frontiers in Immunology*, 9, 1795

# MHCII-NP

## MHC II NP - Prediction of naturally processed MHC II ligands

**Sequences**

Enter sequences in FASTA or plain format

```
>sp|P15848|ARSB_HUMAN Arylsulfatase B OS=Homo sapiens OX=9606 GN=ARSB
PE=1 SV=1
MGPRGAASLPRGPGPRLLLLPVVLPLLLLLLAPPGSGAGASRPPHLVFLADDLGWNDV
GFHGSRI RTPHLDALAAGGVLLDNYTQPLCTPSRSQLLTGRYQIRTLGHQIIWPCQPS
CVPLDEKLLPQLLKEAGYTTMVGKWHLMYRKECLPTRRGFDYFGYLLGSEDIYYSHER
CTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQS
VHEPLQVP E EYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTD
NGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKL
ARGHTNGTKPLDGFVWKTISEGSPSPRIELHNIIDPNFVDSSPCPRNSMAPAKDDSSLP
EYSAFNTSVHAAIRHGNWKLGTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFIDIRD
PEERHDL SREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM
```

Or upload sequences as a text file  No file chosen

# MHCII-NP Results

Seq name	Peptide start	Peptide end	Peptide length	Peptide N motif	C motif	Cleavage probability	score	Cleavage probability percentile	rank							
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	310	324	15	VFVYFPAQDFRCDFK	SVP	PRA	1.75814	0.0	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	2	16	15	GPRGAASLPRGPGPR	MGP	PRR	1.73735	0.02	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	247	261	15	VPEEYLKPYDFIQDK	QVP	DKN	1.4884	0.04	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	384	398	15	SPSPRIELLHNIDPN	GSP	PNF	1.4042	0.05	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	12	26	15	GPGPRLLLPVVLPL	RGP	PLL	1.33714	0.07	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	480	493	14	DPEERHDLRSREYPH	RDP	PHI	1.2645	0.09	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	2	17	16	GPRGAASLPRGPGPR	MGP	RRL	1.10023	0.11	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	33	46	14	APPGSGAGASRPPH	LAP	PHL	1.06464	0.12	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	253	268	16	KPYDFIQDKNRHHYAG		LKP	AGM	1.03988	0.14
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	247	260	14	VPEEYLKPYDFIQDK	QVP	QDK	0.95759	0.16	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	466	479	14	DPPTKTLWLFIDIR	SDP	DRD	0.95486	0.18	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	462	476	15	IPSSDPPTKTLWLF	EIP	FDI	0.86742	0.19	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	69	84	16	TPHLDALAAGGVLLDN		RTP	DNY	0.86541	0.21
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	375	388	14	DVWKTISEGSPSPR	FDV	PRI	0.86177	0.23	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	466	481	16	DPPTKTLWLFIDIRDP		SDP	DPE	0.83011	0.25
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	274	288	15	DEAVGNVTAALKSSG	MDE	SGL	0.81861	0.27	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	480	492	17	DPEERHDLRSREYPH	RDP	PHI	1.2645	0.09	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	92	106	15	TPSRSQLLTGRIQIR	CTP	IRT	0.7967	0.3	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	33	45	13	APPGSGAGASRPP	LAP	PPH	0.7844	0.32	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	384	397	14	SPSPRIELLHNIDP	GSP	DPN	0.76819	0.34	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	510	523	14	VPVYFPAQDFRCDFK	SVP	DPK	0.76819	0.34	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	230	244	15	KPLFLYLALQSVHEP	EKP	EPL	0.76271	0.37	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	334	349	16	SPLLKQKGVKNRELIH		ASP	IHI	0.75419	0.39
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	334	346	13	SPLLKQKGVKNRE	ASP	REL	0.74385	0.41	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	518	532	15	DPRCDPKATGVWGPW	QDP	PWM	0.73955	0.42	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	415	430	16	DSSSLPEYSAFNTSVH		KDD	VHA	0.72819	0.44
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	247	262	16	VPEEYLKPYDFIQDKN	QVP	KNR	0.72168	0.46	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	411	426	16	APAKDSSSLPEYSAFN		MAP	FNT	0.70948	0.48
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	122	135	14	VPLDEKLLPQLLKE	CVP	KEA	0.69567	0.5	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	53	68	16	DDLGWNDVGFHGSRI		ADD	IRT	0.67205	0.51
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	416	430	15	DSSSLPEYSAFNTSVH	DDS	VHA	0.65617	0.53	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	395	407	13	IDPNFVDSPPCPR	NID	PRN	0.6459	0.55	
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	20	35	16	LPVVLPLLLLLLLAPP		LLP	PPG	0.64372	0.57
SP P15848	ARSB_HUMAN	ARYLSULFATASE	B OS=HOMO	SAPIENS	OX=9606	GN=ARSB	PE=1 SV=1	411	424	14	APAKDSSSLPEYSA	MAP	SAF	0.63924	0.58	



**Thank you for attention !!**